doi: 10.1001/jamaoncol.2021.8206.
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead
Affiliations
- PMID: 35266952
- DOI: 10.1001/jamaoncol.2021.8206
Item in Clipboard
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead
JAMA Oncol.
.
No abstract available
Similar articles
-
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.J Clin Oncol. 2024 Mar 10;42(8):973-974. doi: 10.1200/JCO.23.02259. Epub 2024 Jan 30. J Clin Oncol. 2024. PMID: 38290085 No abstract available.
-
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.Eur J Cancer. 2014 Sep;50(13):2303-8. doi: 10.1016/j.ejca.2014.05.024. Epub 2014 Jun 25. Eur J Cancer. 2014. PMID: 24974171 Review.
-
Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PPO.0b013e3181b9c5ec. Cancer J. 2009. PMID: 19826358 Review.
-
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.Curr Oncol Rep. 2009 Jan;11(1):1-2. doi: 10.1007/s11912-009-0001-y. Curr Oncol Rep. 2009. PMID: 19080733 No abstract available.
-
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.Eur J Cancer. 2014 Sep;50(13):2298-302. doi: 10.1016/j.ejca.2014.05.016. Epub 2014 Jun 12. Eur J Cancer. 2014. PMID: 24930623 Review.
Cited by
-
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.Liver Cancer. 2023 Jul 25;13(2):169-180. doi: 10.1159/000531744. eCollection 2024 Apr. Liver Cancer. 2023. PMID: 38751554 Free PMC article.
-
Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study.Blood Adv. 2024 Nov 12;8(21):5539-5541. doi: 10.1182/bloodadvances.2024013600. Blood Adv. 2024. PMID: 39207867 Free PMC article. No abstract available.
-
Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?Leukemia. 2022 Nov;36(11):2743-2747. doi: 10.1038/s41375-022-01699-7. Epub 2022 Sep 13. Leukemia. 2022. PMID: 36100641 No abstract available.
-
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.Transl Lung Cancer Res. 2025 Feb 28;14(2):563-574. doi: 10.21037/tlcr-2025-83. Epub 2025 Feb 27. Transl Lung Cancer Res. 2025. PMID: 40114962 Free PMC article.
-
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas.Pharmacoeconomics. 2025 Jul;43(7):793-803. doi: 10.1007/s40273-025-01485-0. Epub 2025 Mar 29. Pharmacoeconomics. 2025. PMID: 40156682 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
